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Abstract: This study assessed the profile of benzodiazepine (BDZ) users in Lebanon. Adult 
patients visiting the pharmacies with prescriptions of BDZs were included in the study. Seven 
hundred and eighty-six current BDZ users were included, of whom 54.2% were females. Twenty-
three percent reported being alcohol consumers and were mostly males. The two most commonly 
used BDZs were alprazolam (34.6%) and bromazepam (33.6%). The indication for use was 
mainly anxiety (44.4%), insomnia (22.5%), and depression (15.9%). The prescribing physicians 
were primarily psychiatrists (43.2%), followed by general practitioners (29.7%). Forty percent 
had been taking the drug for more than a year. Among those using BDZs for at least 1 month, 
35.5% increased the dose with time. Thirty-three percent reported having experienced side effects. 
Eighteen patients (2.3%) reported taking more than one BDZ concomitantly, while 18.3% were 
taking drugs that should not be prescribed along with BDZs. In conclusion, the use of BDZs is 
highest among females, especially for the treatment of anxiety. Moreover, continuous use of the 
drugs for more than a year as well as significant potential drug interactions was identified.
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Introduction
Nonmedical use of prescription medications is a growing global concern.1 The use of 
prescription drugs seems to be increasing at a faster rate than that of illicit substances.2 
In Lebanon, ~20% of the young adult population is taking psychoactive substances in 
nonmedical aspects that differ from the prescription recommendations.3,4 This practice 
puts the Lebanese population at increased risk for dangerous physical and psychologi-
cal side effects.3 In addition to health implications, this practice has major economic 
consequences. While there is a lack of data on the economic impact of nonmedical 
use of prescription drugs in Lebanon, studies conducted in the US clearly highlighted 
its associated financial burden on society.5
Benzodiazepines (BDZs) are among the most widely and frequently used psy-
choactive substances in the world. They have an important role in clinical medicine 
and are used in numerous clinical conditions like anxiety and sleep disorders, alcohol 
withdrawal, the augmentation of antidepressants and antipsychotics, mania, muscle 
relaxation, seizures, as well as in many non-approved indications.6,7 Their clinical 
use, however, should be monitored closely due to their adverse effects and potential 
for misuse and abuse. Several adverse reactions have been associated with the use 
of BDZs including motor disturbances, cognitive decline, unwanted sedation, and 
reduced coordination.7
Across countries, studies have shown a relatively high prevalence of BDZ use in the 
general population with a somewhat different pattern of use ranging from as low as 6.2% 
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in developed countries up to 36% in developing ones.8–21 In 
the US, a recent report revealed that a 12-month prevalence of 
BDZ use as tranquilizers was 8.6%.22 A prevalence estimate 
of 9.2% BDZ usage was reported from a combined population 
of six European countries.23 The prevalence of BDZ use in an 
elderly population of a Canadian province exceeds 10%.24
Most developed countries have routinely collected data 
on BDZs prescription and consumption; however, limited 
data exist on the rates and patterns of use in Lebanon. 
The main objective of this study is to assess the patterns 
of BDZs use, profile of users in Lebanon regarding their 
demographic characteristics, the clinical indication for use, 
duration of use, perceived side effects, and potential drug–
drug interactions.
Materials and methods
This is an observational study that was conducted at 27 
community pharmacies in Lebanon over a period of 2 years, 
from June 2012 till May 2014. The targeted population were 
ambulating Lebanese patients aged $18 years, recruited in 
various community pharmacies across different regions of 
Lebanon. To ensure a representative sample of adults, the 
pharmacies were randomly selected across the six Lebanese 
governorates: North of Lebanon, Mount Lebanon, Beirut, 
South of Lebanon, Beqaa, and Nabatieh. Patients visiting the 
pharmacies with prescriptions of BDZs were asked if they 
were willing to participate in the study. Family members of 
patients who came to the pharmacies to get the BDZs were 
asked to provide the telephone number of the patients and 
about the possibility to call them. Phone interviews were 
done when patients consented to participate in the study. 
An interview questionnaire was used to collect the data. 
The study was approved by the LAU University Institutional 
Review Board, and a waiver of consent was obtained to fill 
out the questionnaire.
The questionnaire gathered data on sociodemographic 
characteristics including age, sex, place of residence, preg-
nancy, breastfeeding, and alcohol intake. Data on patterns 
of BDZ use included indication(s) for use, specialty of 
prescribing physician, duration of therapy, perceived side 
effects, concomitant medications used, and increase in BDZ 
dose with time.
Data were processed and analyzed through the application 
of the Statistical Package for Social Sciences (version 22; 
IBM Corporation, Armonk, NY, USA). The association of 
BDZ use by sociodemographic variables and indication, 
duration of use, and perceived side effects was assessed by 
applying the chi-square statistical test using a significance 
level of 5%.
Results
sociodemographic characteristics
Table 1 describes the sociodemographic characteristics of 
the 786 sampled BDZ current users, of whom 45.8% were 
males and 54.2% were females, and three were pregnant or 
breastfeeding. The proportion of BDZ users who agreed to 
participate in the study approached 86%. Twenty-three percent 
reported being alcohol consumers, with a significant differen-
tial by age and sex of study participants. Males reported a sig-
nificantly higher proportion of alcohol consumption (33.5%) 
compared to female users (14.9%), even after adjusting for age. 
There were 24 (3.1%) and 21 individuals (2.7%) who reported 
suffering from liver and renal diseases, respectively.
BDZ use characteristics
The two most commonly used BDZs were alprazolam 
(34.6%) and bromazepam (33.6%), followed by clonazepam 
(12.1%) and lorazepam (10%), and the least commonly used 
were diazepam (5.3%), midazolam (3%), and temazepam 
(1.3%). There was a significant differential of type of 
medication used by sex specifically among the younger age 
group of users (20–50 years); the proportion of females 
using bromazepam was significantly higher (34.3%) com-
pared to males (24.6%). Males were more frequent users of 
Table 1 Distribution of sociodemographic characteristics of a 
sample BDZ current user
Frequency
N (%)
sex
Male 352 (45.8)
Female 416 (54.2)
age (years)
20–29 48 (6.3)
30–39 116 (15.1)
40–49 184 (24.0)
50–59 192 (25.0)
60–69 144 (18.8)
70+ 84 (10.9)
geographical distribution
Beirut 172 (22.4)
Beirut suburbs 119 (15.5)
Byblos 67 (8.7)
Jounieh 199 (25.9)
Tripoli 152 (19.8)
saida 59 (7.7)
Total 768 (100.0)
Proportion of alcohol consumption
Male (33.5)
Female (14.9)
BDZ consumers with comorbidities
renal disease (2.7)
liver disease (3.1)
Abbreviation: BDZ, benzodiazepine.
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diazepam (11.2%) and clonazepam (19.0%) compared to 
females (3% and 11.8%, respectively) (Table 2).
The indication for BDZ use was mainly anxiety (44.4%), 
insomnia (22.5%), depression (15.9%), epilepsy (5.7%), 
minor surgery/procedures (5.6%), schizophrenia (1.2%), 
pain (1.0%), muscle spasm (0.4%), and multiple sclerosis 
(0.3%). Reports of anxiety, insomnia, and depression were 
more frequently reported among females than males, while 
epilepsy, pain relief, and surgery seemed to be reported 
more frequently by males compared to females. When sex 
was stratified by age group, the sex differential was signifi-
cant only among the younger age group, that is, those aged 
20–50 years old (Table 3).
Table 4 shows that the distribution of type of BDZ 
medication differs significantly by reported indication for 
BDZ use. The most common drugs prescribed for anxiety, 
insomnia, depression, and pain relief were bromazepam and 
alprazolam; however, clonazepam was the drug of choice 
for epilepsy.
Prescriber of the BDZ and duration of use
The BDZ was usually prescribed by a medical doctor except 
for one case by a pharmacist for insomnia and three cases 
by a dentist for minor surgery. The prescribing physician 
was primarily a psychiatrist (43.2%), a general practitioner 
(29.7%), or a surgeon (2.3%). There were nine cases where 
the BDZ was prescribed by a pediatrician, four for anxiety, 
four for insomnia, and one for pain relief.
The medical indication for prescribing BDZ varied sig-
nificantly by the prescribing physician specialty. Psychiatrists 
prescribed BDZs mainly for anxiety and depression (65%), 
followed by general practitioners (56%), cardiologists (53%), 
and other specialists (49%).
Approximately 15% of the patients were taking BDZ on 
an “as-needed” basis, and 40% had been taking the drug for 
more than a year. The duration of BDZ use for .1 year did 
differ significantly by the specialty of the prescribing physi-
cian; it was reported as 52% among cardiologists and 43% by 
psychiatrists compared to 34% by general practitioners and 
other specialists. Table 5 shows the distribution of duration 
of therapy by physician specialty.
interval for BDZ dosage increase and 
perceived side effects
All the patients who had used the BDZ medication for at least 
1 month were asked to report on the timing of the increase 
in the BDZ dose and its side effect. The proportion of the 
sample who had not started their BDZ medication yet was 
6.1%. Among those who had used their medication for at least T
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1 month, 64.5% did not increase the dose, while 7.6% did 
after 1 month, 3.6% after 2 months, 8.9% after 3 months, 
and 9.4% after 6 months. There was no differential in the 
reported BDZ dosage increase by participant sex controlling 
for BDZ user age interval in years. Only 1.2% of all BDZ 
users reported having to take a higher dose than recom-
mended by the manufacturers.
Thirty-three percent (237 cases) of the surveyed users 
reported having experienced side effects due to the intake 
of BDZ. The reported side effects were restlessness (38%), 
display of aggressive behavior (15.6%), headache (11.4%), 
delusions (10.5%), inappropriate behavior (10.1%), night-
mares (9.7%), and stomach upset (4.6%). The reported per-
ceived side effects did not vary significantly by sex and age 
of the study participants. However, there was a significant 
variation in prevalence of side effects by type of medication 
prescribed. Perception of side effects was reported most 
frequently among those taking bromazepam and the least 
among those on diazepam.
Perception of reported side effects was significantly 
associated with the medication duration of use being more 
frequent among those who use it on an as-needed basis and 
among those who have been using it for .2 months.
Duplication of BDZ drug therapy
In order to check for possible BDZ drug duplication therapy, 
the names of the different BDZs were cross-checked and 
analyzed. The duplication of therapy was noted among 
18 patients (2.3%) only.
Use of other medications
Patients were asked whether they were taking other media-
tion with BDZ, and 56.1% reported taking other medications. 
Among those who reported taking other medication, 18.3% 
of the cases were taking drugs that should not be prescribed 
along with BDZs. The type of potential drug–drug interaction 
was analyzed, and the results are shown in Table 6.
Discussion
The discovery of BDZs in the late 50s was met with a lot 
of excitement by physicians leading to an alarming rise of 
their use around the world.1 This study assessed the profile of 
BDZ users in Lebanon. Among Lebanese BDZ users, there 
was a slight preponderance of females, a finding consistent 
with previously published trials.8,15,16,20,25 Facts that might 
explain this finding are the higher prevalence of anxiety 
among females, as well as the higher life expectancy and 
higher compliance described in females.13,26T
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Most BDZs are considered to have similar efficacy; 
therefore, selection is based on pharmacokinetic consider-
ations and the US Food and Drug Administration (FDA)-
labeled indication. The two most common types of BDZs 
used were alprazolam and bromazepam, both of which are 
intermediate acting with a relatively rapid onset of action 
as compared to other BDZs.27 Bromazepam and alprazolam 
were also found to be mostly used in Pakistan.16,18 Clonaze-
pam was mainly used for seizure disorders as it is one of the 
few BDZs approved by the FDA for this indication. One of 
the least-used agents was diazepam characterized by its much 
longer half-life and increased tolerance.27
According to the World Health Organization, anxiety is 
the most prevalent mental disorder.28 In addition, ~30% of a 
variety of adult samples drawn from different countries report 
having insomnia.29 Among the Lebanese BDZ users, 44.4% 
were taking the BDZ for anxiety and 22.5% for insomnia fol-
lowed by 16% for depression. Studies suggest that BDZ can 
be an effective option for patients with anxiety with minimal 
roles for other indications as depression, muscle relaxation, 
and schizophrenia. Furthermore, the better safety profile 
of the newer non-BDZ hypnotics (ie, zolpidem, zaleplon, 
eszopiclone, and ramelteon) makes them better first-line 
pharmacological choices for the management of insomnia. 
Despite that, numerous studies have shown that BDZs are 
overprescribed for extended periods in many countries.30–32 
The findings of this study indicated that a proportion of 
patients were inappropriately using BDZs for indications like 
pain management and continued use after minor surgeries.
A little less than half of the patients reported continuous 
use of BDZs for more than a year. Among prescribers, 
cardiologists and psychiatrists tend to prescribe BDZs 
for a longer period of time which might be explained by 
the chronic diseases they usually treat. Doses used were 
increased by ~35% after the first month that could be due 
to tolerance to the agents but remained therapeutic. BDZs 
are associated with troublesome sedation and cognitive 
impairment as well as tolerance and dependence with pro-
longed use.33 Recommendations for the duration of treat-
ment with BDZ especially in elderly are usually no more 
than 2–4 weeks of continuous use.34 In resistant or critical 
severe cases, BDZs should not be used for .8–12 weeks, 
Table 4 Distribution of type of BDZ medication by indication of use
BDZ type BDZ drug indication Total P-value
Anxiety Insomnia Depression Epilepsy/MS/SCZ Pain/intoxication
N (%) N (%) N (%) N (%) N (%) N (%)
Bromazepam 125 (36.7) 54 (31.2) 45 (36.9) 9 (15.5) 25 (33.8) 258 (33.6) 0.000
lorazepam 29 (8.5) 24 (13.9) 13 (10.7) 5 (8.6) 6 (8.1) 77 (10.0)
Diazepam 14 (4.1) 4 (2.3) 6 (4.9) 7 (12.1) 10 (13.5) 41 (5.3)
alprazolam 140 (41.1) 54 (31.2) 42 (34.4) 12 (20.7) 18 (24.3) 266 (34.6)
Midazolam/temazepam 4 (1.2) 23 (13.3) 2 (1.6) 0 (0.0) 4 (5.4) 33 (4.3)
clonazepam 29 (8.5) 14 (8.1) 14 (11.5) 25 (43.1) 11 (14.9) 93 (12.1)
Total 341 (100) 173 (100) 122 (100) 58 (100) 74 (100) 768 (100)
Abbreviations: BDZ, benzodiazepine; Ms, multiple sclerosis; scZ, schizophrenia.
Table 5 Distribution of duration of therapy by physician specialty
Duration of therapy Physician specialty Total
Frequency (%)Psychiatry/
neurology
Frequency (%)
Cardiology
Frequency (%)
General 
practice
Frequency (%)
Other specialty
Frequency (%)
as needed 52 14 37 15 118
(15.7) (13.0) (16.2) (15.0) (15.4)
2 weeks–2 months 33 8 38 14 93
(9.9) (7.4) (16.7) (14.0) (12.1)
2–6 months 50 11 30 20 111
(15.1) (10.2) (13.2) (20.0) (14.5)
6–12 months 54 19 47 17 137
(16.3) (17.6) (20.6) (17.0) (17.8)
.1 year 143 56 76 34 309
(43.1) (51.9) (33.3) (34.0) (40.2)
Total 332 108 228 100 768
(100.0) (100.0) (100.0) (100.0) (100.0)
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as tolerance and physical and psychological dependence 
can occur. The findings of this study highlight the scale 
of the need for interventions to reinforce the adherence to 
guidelines by having clinicians use the lowest therapeutic 
doses for the briefest duration of time.
The study participants were prescribed BZDs by qualified 
health care providers except for cases where BDZs were 
prescribed by community pharmacists not entitled to dis-
pense controlled substances. Nine adults were prescribed 
BDZs by pediatricians which raises the question about the 
justification of those prescriptions. Previously published evi-
dence showed the easy access to prescription medications in 
Lebanon and documented a lack of awareness on the dangers 
of prescription misuse. The role of the Lebanese pharmacists 
in dispensing prescription drugs without medical prescrip-
tions has been identified as a major contributor, while the role 
of the Lebanese government in controlling the drug supply 
system was described as insufficient.3,4
It was found that 23% of BDZ users reported being alco-
hol consumers and were more likely to be males. The higher 
percentage of males being alcohol consumers as compared 
to females is consistent with older studies as females may 
carry a lower genetic risk for alcohol use disorders while 
males have fewer perceived social sanctions for drinking.35,36 
Alcohol has a documented potentiation effect on gamma-
aminobutyric acid receptors. In addition to alcohol intake, 
a significant proportion of the study participants reported 
taking other medications that interacted significantly with 
BDZ either by affecting its metabolism (antifungals, oral 
contraceptives, selective serotonin reuptake inhibitors) or 
by potentiating its central nervous system depression effects. 
These important drug–drug interactions are associated with 
drug-induced death, drug overdoses, and traffic accidents or 
fatalities and require adequate patient education and aware-
ness by prescribers and pharmacists.28
One of the limitations of this study is its observational 
nature. Not all Lebanese pharmacies were included in the 
sample; however, the big number of patients recruited from 
different geographical areas as well as the long duration 
of the study diluted this limitation and made the sample 
representative. Additionally, patients’ self-reporting of side 
effects to BDZ could have been subjective and confounded 
by patient’s disease states and/or concomitant medications. 
Also, it would be possible that more patients were taking 
higher doses than recommended by the manufacturer than 
being reported and were reluctant to admit the misuse of 
their medications.
Despite the mentioned limitations, the major strength of 
this study resides in the fact that it was the first one to report 
on BDZ use across a large number of individuals from across 
the country.
Conclusion
Understanding the patterns of BDZ use in the Lebanese 
community is an essential first step toward the implementa-
tion of interventions to reduce its misuse and abuse. To our 
knowledge, the present study is the first to report patterns of 
BDZ in the Lebanese adult ambulatory population. Results 
showed that the use of this class of medication is highest 
among females especially for the treatment of anxiety. More-
over, continuous use of the drugs for more than a year as 
well as significant potential drug interactions was identified. 
A collaborative effort of governmental bodies and health care 
providers is recommended to educate, regulate, and promote 
the appropriate and safe use of BDZ.
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